Literature DB >> 27814273

Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma.

Zhengrong Wu, Liangjing Zhou, Guoping Ding, Liping Cao.   

Abstract

BACKGROUND: The miR-212 was among the top differentially expressed miRNAs in pancreatic ductal adenocarcinoma (PDAC).
OBJECTIVE: The aim of this study was to investigate the expression of miR-212 in PDAC and evaluate its correlation with major clinicopathologic features and patients' survival.
METHODS: Fluorescence in situ hybridization (FISH) was adopted to examine miRNA expression in 45 pancreatic cancer and 20 normal pancreatic tissues. The relationship of miR-212 expression with clinicopathologic parameters and clinical outcome was evaluated.
RESULTS: miR-212 was confirmed to have significantly higher expression in PDAC compared with normal pancreatic tissues (51.1% vs 10%, p< 0.01). High expression of miR-212 was significantly associated with tumor size (p = 0.048) and tumor stage (p = 0.023). Moreover, in univariant analysis, patients with high expression of miR-212 demonstrate significantly poorer overall survival (p= 0.02).
CONCLUSIONS: High expression of miR-212 in PDAC is associated with shorter overall survival. It may be not only a potential prognostic marker, but also a possible therapeutic target in PDAC.

Entities:  

Keywords:  Pancreatic neoplasms; Prognosis; microRNA-212

Mesh:

Substances:

Year:  2017        PMID: 27814273     DOI: 10.3233/CBM-160671

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  7 in total

Review 1.  The functions and targets of miR-212 as a potential biomarker of cancer diagnosis and therapy.

Authors:  Wenjun Chen; Jing Song; Hongjun Bian; Xia Yang; Xiaoyu Xie; Qiang Zhu; Chengyong Qin; Jianni Qi
Journal:  J Cell Mol Med       Date:  2020-01-13       Impact factor: 5.310

2.  MicroRNA-212 Targets Mitogen-Activated Protein Kinase 1 to Inhibit Proliferation and Invasion of Prostate Cancer Cells.

Authors:  Bo Hu; Xunbo Jin; Jianbo Wang
Journal:  Oncol Res       Date:  2018-01-10       Impact factor: 5.574

Review 3.  MiR-212 value in prognosis and diagnosis of cancer and its association with patient characteristics: a systematic review and meta-analysis.

Authors:  Sara Raji; Mehrdad Sahranavard; Mahdi Mottaghi; Amirhossein Sahebkar
Journal:  Cancer Cell Int       Date:  2022-04-26       Impact factor: 6.429

4.  Elevated expression of exosomal microRNA-21 as a potential biomarker for the early diagnosis of pancreatic cancer using a tethered cationic lipoplex nanoparticle biochip.

Authors:  Xiaofan Pu; Guoping Ding; Mingjie Wu; Senhao Zhou; Shengnan Jia; Liping Cao
Journal:  Oncol Lett       Date:  2020-01-15       Impact factor: 2.967

5.  Negative feedback loop of ERK/CREB/miR-212-3p inhibits HBeAg-induced macrophage activation.

Authors:  Wenjun Chen; Hongjun Bian; Xiaoyu Xie; Xia Yang; Benjun Bi; Chunliu Li; Yuejuan Zhang; Qiang Zhu; Jing Song; Chengyong Qin; Jianni Qi
Journal:  J Cell Mol Med       Date:  2020-08-07       Impact factor: 5.310

6.  Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation.

Authors:  Guoping Ding; Xiaodong Xu; Dan Li; Yuhao Chen; Weimin Wang; Dongnan Ping; Shengnan Jia; Liping Cao
Journal:  Cell Death Dis       Date:  2020-10-22       Impact factor: 8.469

7.  Novel therapies targeting hypoxia mechanism to treat pancreatic cancer.

Authors:  Wenhao Luo; Jiangdong Qiu; Lianfang Zheng; Taiping Zhang
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.